Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Drug Safety Committee To Discuss Use Of Post-Marketing Studies May 19

This article was originally published in The Pink Sheet Daily

Executive Summary

The Drug Safety & Risk Management Advisory Committee will consider the utility of various types of post-market studies in detecting and quantifying risk.

You may also be interested in...

Drug Safety Surveillance Based On Medicare Data Should Top List Of FDA Priorities

Implementation of the Medicare drug benefit provides an opportunity for an active surveillance system to collect drug safety data, Drug Safety & Risk Management Advisory Committee members say. Active surveillance can act as a safety net for FDA's adverse events signaling system.

NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance

FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts